Phase 3 Readout
NSRX: Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic R
July 12, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 12, 2026
- Company
- Nasus Pharma Ltd (NSRX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic R
- Company
- Nasus Pharma Ltd (NSRX)
- Indication
- Anaphylaxis Food